OXB, a specialized cell and gene therapy CDMO, has launched a “Fast-track” development and manufacturing offering to address the urgent needs of the biotechnology sector. The service is specifically tailored for clients utilizing lentiviral (LV) and adeno-associated viral (AAV) vectors, providing an accelerated pathway to Good Manufacturing Practice (GMP) standards.
Key performance and timeline benchmarks:
-
Timeline Reduction: OXB claims its program can shorten the industry-standard 15-month lead time to GMP manufacture down to as little as seven months. For lentiviral vectors, timelines can be condensed from the typical 12–18 months to just nine months.
-
Proprietary Technology: The offering leverages OXB’s inAAVate and LentiVector platforms. These “plug-and-play” systems utilize advanced analytics and platform datasets to bypass traditional developmental bottlenecks while maintaining high titers and consistent performance at scale.
-
Integrated Workflow: Maximum efficiency is achieved by consolidating vector design, production, purification, and fill-finish operations into a seamless process.
According to OXB Chief Business Officer Sébastien Ribault, PhD, this initiative aims to slash development timelines by up to 50%. By removing manufacturing hurdles, OXB enables biotech firms to reach clinical and regulatory milestones faster, ultimately accelerating patient access to critical cell and gene therapies.